On Monday, the U.S. Food and Drug Administration (FDA) approved Gammagard Liquid as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). “As the standard of care for the treatment of CIDP, IG therapy is thought to help normalize compromised immune systems through immunomodulatory mechanisms,” said Mamatha Pasnoor, M.D., professor in the Department of Neurology at the University of Kansas Medical Center and a neurologist with The University of Kansas Health System. “Because CIDP is a progressive and complex disease, multiple treatment options are needed, and clinicians now have an additional therapy that can help adults with CIDP manage their disease.”